KATHY WILSON: Open Payments
NPI 1750158507 · CAPE GIRARDEAU, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,122 in 67 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $860 · 2025 $1,122
Food & beverage: $1,122
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 13 | $228 |
| Vanda Pharmaceuticals Inc. | 13 | $175 |
| Otsuka America Pharmaceutical, Inc. | 10 | $155 |
| ABBVIE INC. | 14 | $137 |
| Teva Pharmaceuticals USA, Inc. | 2 | $118 |
| Neurocrine BioSciences, Inc. | 5 | $112 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $80 |
| Lundbeck LLC | 3 | $62 |
| Janssen Pharmaceuticals, Inc | 2 | $39 |
| Axsome Therapeutics, Inc. | 1 | $15 |
Products named: ARISTADA, REXULTI, FANAPT, VRAYLAR, UZEDY, INGREZZA, CAPLYTA, SPRAVATO.
Industry payments across MO — which companies pay providers there.
